{"id":"inotuzumab-ozogamicin-ino","safety":{"commonSideEffects":[{"rate":"70","effect":"Thrombocytopenia"},{"rate":"65","effect":"Neutropenia"},{"rate":"50","effect":"Anemia"},{"rate":"40","effect":"Infection"},{"rate":"35","effect":"Nausea"},{"rate":"25","effect":"Vomiting"},{"rate":"20","effect":"Hepatotoxicity"},{"rate":"5","effect":"Sinusoidal obstruction syndrome (SOS)"}]},"_chembl":null,"_dailymed":{"setId":"cc7014b1-c775-411d-b374-8113248b4077","title":"BESPONSA (INOTUZUMAB OZOGAMICIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets CD22, a surface antigen expressed on B-lineage hematologic malignancies. Upon binding, the antibody-drug conjugate is internalized and releases calicheamicin, which causes DNA double-strand breaks and apoptosis. This targeted delivery mechanism concentrates cytotoxicity on malignant B cells while sparing normal tissues.","oneSentence":"Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing toxin directly to tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:19.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)"},{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT07443488","phase":"PHASE2","title":"Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-14","conditions":"HSCT, Ph+ ALL","enrollment":20},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05456698","phase":"PHASE2","title":"Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-10-18","conditions":"Acute Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT07238907","phase":"","title":"A Multi-center Retrospective Study of INO Treating B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-01","conditions":"Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin","enrollment":102},{"nctId":"NCT05940961","phase":"PHASE2","title":"Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL","status":"RECRUITING","sponsor":"Sheng-Li Xue, MD","startDate":"2022-08-01","conditions":"ALL, MRD-positive, Hematopoietic Stem Cell Transplantation","enrollment":42},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":"Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT06861348","phase":"PHASE2","title":"Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-01","conditions":"Leukemia, Lymphocytic, Acute","enrollment":23},{"nctId":"NCT05597085","phase":"","title":"A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-08","conditions":"Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT06554626","phase":"PHASE2","title":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-08-15","conditions":"Precursor B-Cell Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT06025682","phase":"","title":"Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-04-04","conditions":"Acute Lymphoblastic Leukemia, Infections, Bacterial Infections","enrollment":158},{"nctId":"NCT03249870","phase":"PHASE2","title":"Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL","status":"UNKNOWN","sponsor":"Versailles Hospital","startDate":"2017-12-28","conditions":"Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)","enrollment":130},{"nctId":"NCT03991884","phase":"PHASE1","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-09-24","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04456959","phase":"","title":"InO - A Retrospective Study of UK Patients With Leukaemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-06","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["InO vs. R3 randomisation in SR"],"phase":"marketed","status":"active","brandName":"Inotuzumab ozogamicin (INO)","genericName":"Inotuzumab ozogamicin (INO)","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing toxin directly to tumor cells. Used for Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), Relapsed or refractory B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}